Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research

RMJ. 2019; 44(3): 477-481


Immunohistochemical analysis of Hodgkin’s lymphoma in population of Sindh, Pakistan

Abdul Aziz Shaikh aziz,Dr Shaista Khan,Saira Bugti Bhugti Saira,Junaid Ali Thebo,Ghulam Nabi Rajper,Dr. Muhammad Hassan Khaskheli.

Abstract
Objective: To confirm Hematoxylin and Eosin (H&E) diagnosed and suspicious cases of Hodgkin’s lymphoma then sub-classify & differentiate from other mimicries based on panel of CD markers.
Methodology: This descriptive cross sectional study used non-probability purposive sampling and cases were collected at Department of Pathology, Liaquat University of Medical and Health Sciences (LUMHS) Jamshoroa and Diagnostic and Research Laboratory Hyderabad. Chi square test was used to compare discrete variables. Pearson’s correlation coefficients were used to test the correlation between continuous variables.
Results: Out of 100 cases, 80 were of Hodgkin's lymphoma (HL), based on panel of Cluster differentiation (CD) markers expression. Among these, 70 were of Classical Hodgkin's lymphoma (CHL), based on either positivity of both CD30 and CD15 or any one of them with negativity of CD45 for H&RS cells. The remainders 10 were of Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL), showing positivity for CD45 and negativity for CD30 & CD15 for Lymphocytic & Histiocytic (L&H) cells in all cases, but also shown positivity for CD20 in 90% cases.
Conclusion: The Hodgkin’s lymphoma originates from mature germinal center B-lymphocyte with phenotypically expression of CD 15 & CD 30, but in our investigation of immunochemistry showed that CD 20 positivity is not unusual. Lymphocytic and histiocytic cells of NLPHL expressed CD20 in 90% and CD45 in 100% cases This is mandatory for H&E diagnosed and suspicious cases of HL, to confirm on panel of CD markers, before giving the opinion.

Key words: Hodgkin's disease, Non Hodgkin lymphoma, CD markers, Nodular lymphocyte.



Similar Articles

Exploring the Alzheimer's disease neuroepigenome: recent advances and future trends.
Zhang H, Elefant F
Neural regeneration research. 2022; 17(2): 325-327

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12

Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL, Gómez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-Díaz JC, Sánchez-González VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37

A neuron's ambrosia: non-autonomous unfolded protein response of the endoplasmic reticulum promotes lifespan.
Homentcovschi S, Higuchi-Sanabria R
Neural regeneration research. 2022; 17(2): 309-310


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites